- Home
- EFT vs LRMR Comparison
EFT vs LRMR Comparison
Compare EFT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFT | LRMR |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.1M | 276.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EFT | LRMR |
|---|---|---|
| Price | $11.48 | $3.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 100.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.10 | $1.61 |
| 52 Week High | $13.44 | $5.37 |
Technical Indicators
Market Signals| Indicator | EFT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 38.06 |
| Support Level | $11.45 | $3.12 |
| Resistance Level | $11.60 | $3.62 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 84.62 | 9.60 |
Price Performance
Historical ComparisonAbout EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.